Dr. Aylin Sertkaya, an ERG senior economist and vice president, designs and conducts economic and policy analyses in support of a wide variety of public policy initiatives for federal and state agencies. Throughout her career at ERG, she has formed and led teams of economists, statisticians, scientists, and nationally recognized subject experts to support dozens of high-profile policy initiatives, working closely with federal agency economists, researchers, and policymakers. Her work has been published in peer-reviewed journals, including JAMA Network Open, American Journal of Infection Control, Human and Ecological Risk Assessment, Applied Health Economics and Health Policy, and Clinical Trials, She has led ERG’s economic and policy analysis practice for over 15 years. 

Aylin received a Recognition Award from the Food and Drug Administration for her work on effective quality systems and risk management approaches as part of FDA’s cGMPs (current Good Manufacturing Practices) in the 21st Century initiative. She has held several leadership positions in the Society for Risk Analysis, including president of SRA’s New England chapter, chair of its Economics and Benefit Analysis Specialty Group, and chair of numerous sessions at SRA meetings. She received the SRA Recognition Award for the workshop on expert elicitation methods that she has co-organized for SRA annual meetings since 2008. She has also served on the National Academies of Sciences, Engineering, and Medicine (NASEM) Committee tasked with examining the long-term health and economic effects of antimicrobial resistance in the United States and contributing to the 2021 NASEM book, Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Aylin holds a Ph.D. in economics and a B.A. in physics and economics, with a minor in mathematics.